BioSpace News Archive

BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap

BioSpace’s ⁠Lori Ellis⁠ and ⁠Chantal Dresner⁠ bring live updates from ⁠day three of #DIA2024⁠ in San Diego.

June 20, 2024
·
1 min read
Drug Development

Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Trial in Women

Gilead Sciences reported zero cases of HIV infection occurred in the lenacapavir candidate group, compared to 16 cases in the Truvada arm and 39 incidents for those treated with Descovy, Gilead’s approved daily PrEP pills.

June 20, 2024
·
2 min read
·
Kate Goodwin
Policy

How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs

The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue.

June 20, 2024
·
5 min read
·
Ben Hargreaves
FDA

Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy

On the heels of a Phase III flop for Pfizer’s Duchenne muscular dystrophy gene therapy candidate, the FDA has green lighted the expanded use of Sarepta Therapeutics’ Elevidys.

June 20, 2024
·
6 min read
·
Tyler Patchen
Deals

Deep Dive: Biopharma M&A Activity Picks Up Steam

The pace of mergers and acquisitions has accelerated. In this deep dive, BioSpace takes a closer look at the nature of recent deals and the players involved.

June 20, 2024
·
2 min read
·
Jef Akst